reMYND’s proprietary TAU[P301L] transgenic, modeling a progressive tau-o-pathy and therefore serving as an excellent model for FTD and Alzheimer’s disease, is now being complemented by the TAU[P301S] model and extended into an bigenic APPxTAU model combining both Abeta and tau pathology.

TAU brainstem

Figure 1. AT100-responsive pathological tau levels (A) in brainstem of 8 month old TAU[P301L] mice, (B) in midbrain of 3-month old APP[V717I] x TAU[P301L] mice.